Inventor · disambiguated record
Ivar M. Mcdonald
Also filed as: MCDONALD IVAR · MCDONALD IVAR M
28 granted patents·16 pending applications·101 citations·filing 2009–2025
95Inventor score
Files withBRISTOL MYERS SQUIBB CO37COOK II JAMES H3MCDONALD IVAR M2LENTZ KIMBERLEY A1ROCHE INNOVATION CT COPENHAGEN AS1
Top patents by PatentIndex Score
44 records- 0195US11359197B2Antisense oligonucleotides targeting alpha-synuclein and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Jun 14, 2022·4 cites·18 claims
- 0295US10869934B2Antiproliferative compounds and conjugates made therefromBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Dec 22, 2020·8 cites·1 claims
- 0393US9526801B2Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and usingBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Dec 27, 2016·13 cites·41 claims
- 0491US7863291B2Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligandsBRISTOL MYERS SQUIBB CO·Filed 2009·Granted Jan 4, 2011·22 cites·14 claims
- 0589US11447775B2Antisense oligonucleotides targeting alpha-synuclein and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Sep 20, 2022·3 cites·20 claims
- 0689US10398783B2Antiproliferative compounds and conjugates made therefromBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Sep 3, 2019·7 cites·4 claims
- 0788US10669272B2Substituted naphthyridinone compounds useful as T cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Jun 2, 2020·4 cites·13 claims
- 0888US2025136988A1Antisense oligonucleotides targeting alpha-synuclein and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2024·Application pending·0 cites
- 0987US9527871B2Benzodiazepine dimers, conjugates thereof, and methods of making and usingBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Dec 27, 2016·5 cites·43 claims
- 1087US8309577B2Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligandsCOOK II JAMES H·Filed 2009·Granted Nov 13, 2012·10 cites·18 claims
- 1185US11866430B2Naphthyridinone compounds useful as T cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Jan 9, 2024·3 cites·11 claims
- 1285US9676794B2Benzodiazepine dimers, conjugates thereof, and methods of making and usingBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jun 13, 2017·3 cites·1 claims
- 1381US12180478B2Antisense oligonucleotides targeting alpha-synuclein and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2022·Granted Dec 31, 2024·0 cites·20 claims
- 1480US9796713B2Tricyclic compounds as alpha-7 nicotinic acetylcholine receptor ligandsBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Oct 24, 2017·2 cites·9 claims
- 1580US9708323B2Tricyclic compounds as alpha-7 nicotinic acetylcholine receptor ligandsBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Jul 18, 2017·2 cites·12 claims
- 1678US11613554B2Phosphorous (V)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophoshorous (V) compoundsBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Mar 28, 2023·1 cites·17 claims
- 1776US8507516B2Azabicyclic compounds as alpha-7 nicotinic acetylcholine receptor ligandsMCDONALD IVAR M·Filed 2010·Granted Aug 13, 2013·4 cites·3 claims
- 1875US8278320B2Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligandsMCDONALD IVAR M·Filed 2010·Granted Oct 2, 2012·4 cites·14 claims
- 1974US12077558B2Phosphorus (V)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophosphorus (V) compoundsBRISTOL MYERS SQUIBB CO·Filed 2023·Granted Sep 3, 2024·0 cites·20 claims
- 2074US8481555B2Aza-bicyclic amine N-oxide compounds as alpha-7 nicotinic acetylcholine receptor ligand pro-drugsLENTZ KIMBERLEY A·Filed 2011·Granted Jul 9, 2013·6 cites·9 claims
- 2174US2025327072A1Antisense oligonucleotides targeting alpha-synuclein and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2025·Application pending·0 cites
- 2267US11713316B2Substituted naphthyridinone compounds useful as T cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Aug 1, 2023·0 cites·11 claims
- 2366US11058767B2CAMK2D antisense oligonucleotides and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Jul 13, 2021·0 cites·17 claims
- 2466US2015094309A1Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligandsBRISTOL MYERS SQUIBB CO·Filed 2014·Application pending·0 cites
- 2565US2014221377A1Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor LigandsBRISTOL MYERS SQUIBB CO·Filed 2014·Application pending·0 cites
- 2664US10112975B2Benzodiazepine dimers, conjugates thereof, and methods of making and usingBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Oct 30, 2018·0 cites·1 claims
- 2763US12241065B2Antisense oligonucleotides targeting alpha-synuclein and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Mar 4, 2025·0 cites·11 claims
- 2863US9822144B2Benzodiazepine dimers, conjugates thereof, and methods of making and usingBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Nov 21, 2017·0 cites·1 claims
- 2963US9822112B2Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and usingBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Nov 21, 2017·0 cites·1 claims
- 3062US9676775B2Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and usingBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jun 13, 2017·0 cites·1 claims
- 3162US2013131064A1Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor LigandsBRISTOL MYERS SQUIBB CO·Filed 2013·Application pending·0 cites
- 3262US2025188463A1Antisense oligonucleotides targeting alpha-synuclein and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2025·Application pending·0 cites
- 3361US10954238B1Substituted naphthyridinone compounds useful as T cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Mar 23, 2021·0 cites·11 claims
- 3460US2024190890A1Mk2 inhibitors and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2023·Application pending·0 cites
- 3559US2016101104A1Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligandsBRISTOL MYERS SQUIBB CO·Filed 2015·Application pending·0 cites
- 3658US2018037581A1Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and usingBRISTOL MYERS SQUIBB CO·Filed 2017·Application pending·0 cites
- 3758US2015342935A1Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligandsBRISTOL MYERS SQUIBB CO·Filed 2015·Application pending·0 cites
- 3857US2021378652A1Camk2d antisense oligonucleotides and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2021·Application pending·0 cites
- 3956US2012035178A1Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor LigandsCOOK II JAMES H·Filed 2011·Application pending·0 cites
- 4056US2012035189A1Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor LigandsCOOK II JAMES H·Filed 2011·Application pending·0 cites
- 4153US2022213484A1Angptl2 antisense oligonucleotides and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 4251US2023089255A1Combinations of dgk inhibitors and checkpoint antagonistsBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 4345US2022119811A1Alpha-synuclein antisense oligonucleotides and uses thereofROCHE INNOVATION CT COPENHAGEN AS·Filed 2019·Application pending·0 cites
- 4437US7977362B2Alpha-(N-benzenesulfonamido)cycloalkyl derivativesBRISTOL MYERS SQUIBB CO·Filed 2010·Granted Jul 12, 2011·0 cites·31 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →